Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 2, 2005, Pages 209-213

  Alou, Luis ^a   Aguilar, Lorenzo ^a   Sevillano, David ^a   Giménez, María José ^a   Echeverría, Olatz ^a   Gómez Lus, María Luisa ^a   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Ceftazidime; Continuous infusion; P. aeruginosa; Pharmacodynamics

Indexed keywords

CEFTAZIDIME;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; INOCULATION; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PREVALENCE; PSEUDOMONAS AERUGINOSA; STEADY STATE;

CEFTAZIDIME; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 14744304766     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh536     Document Type: Article

References (19)

1. Bouza, E., García-Garrote, F., Cercenado, E. et al. (1999). Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. Antimicrobial Agents and Chemotherapy 43, 981-2.
2. Mouton, J. W. & Hollander, J. G. (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38, 931-6.
3. Vogelman, B. & Craig, W. A. (1986). Kinetics of antimicrobial activity. Journal of Pediatrics 108, 835-40.
4. Piccoli, L., Larosa, L. & Marchetti, F. (2003). Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion. Journal of Antimicrobial Chemotherapy 52 1047-8.
5. Ebert, S. C. & Craig, W. A. (1990). Pharmacodynamic properties of antibiotics: Application in drug monitoring and dosage regimen design. Infection Control and Hospital Epidemiology 11 319-26.
6. Craig, W. A. & Ebert, S. C. (1992). Continuous infusion of β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 36 2577-83.
7. Benko, A. S., Cappelletty, D. M., Kruse, J. A. et al. (1996). Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrobial Agents and Chemotherapy 40, 691-5.
8. Nicolau, D. P., Nightingale, C. H., Banevicius, M. A. et al. (1996). Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrobial Agents and Chemotherapy 40, 61-4.
9. National Committee for Clinical Laboratory Standards (1992). Methods for Determining Bactericidal Activity for Antimicrobial Agents. Tentative Guideline M26-T. NCCLS, Villanova, PA, USA.
10. Blaser, J., Stone, B. B. & Zinner, S. H. (1985). Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrobial Agents and Chemotherapy 27, 343-9.
11. Blaser, J., Stone, B. B., Groner, M. C. et al. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and the emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-60.
12. Nicolau, D. P., Lacy, M. K., McNabb, J. et al. (1999). Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patient with nosocomial pneumonia. Infectious Diseases in Clinical Practice 8, 45-9.
13. Lipman, J., Gomersall, C. D., Gin, T. et al. (1999). Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 43, 309-11.
14. Harris, A. (1996). Ceftazidima en infusion continua. Revista Española de Quimioterapia 9, Suppl. 5, 53-9.
15. Andrews, J. M. (1999). Microbiological assays. In Clinical Antimicrobial Assays, 1st edn. (Reeves, D. S., Wise, R., Andrews, J. M., et al. Eds.), pp. 35-44. Oxford University Press, Oxford, UK.
16. Bouza, E., García-Garrote, F., Cercenado, E. et al. (2003). Pseudomonas aeruginosa: estudio multicéntrico en 136 hospitales españoles. Revista Española de Quimioterapia 16 41-52.
17. MacGowan, A. P. & Bowker, E. (1998). Continuous infusion of β-lactam antibiotics. Clinical Pharmacokinetics 35, 391-402.
18. Mouton, J. W. & Vinks, A. A. (1996). Is continuous infusion of β-lactam antibiotics worthwhile? - efficacy and pharmacokinetic considerations. Journal of Antimicrobial Chemotherapy 38, 5-15.
19. Roubaux, M., Dube, L., Caillon, J. et al. (2001). In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. Journal of Antimicrobial Chemotherapy 47, 617-22.